Involvement of the disulfidptosis-related immune checkpoint gene, CD276, in glioblastoma malignant phenotype and poor prognosis

Background Immunotherapy has promise for glioblastoma multiforme (GBM) treatment and disulfidptosis, a form of cell death involving disintegration of the actin cytoskeleton, is a potential target. The aim of the current study was to identify genes associated with disulfidptosis-related immune checkpoints in GBM and to analyze connections with malignancy.